tbuckley/cabot-search huggingface dataset:
A Case Report of Advanced Pancreatic Neuroendocrine Tumor Treated with Chemotherapy for Cisplatin Containing Resimen Followed by Everolimus in Combination with Octreotide LAR
Authors: K. Suzuki, S. Kanno, H. Wakasugi, M. Itoh, K. Fujii, A. Goto
Journal: Annals of Oncology (2012)
Transient Sox9 Expression Facilitates Resistance to Androgen-Targeted Therapy in Prostate Cancer
Authors: Mannan Nouri, Shabnam Massah, Josselin Caradec, Amy A. Lubik, Na Li, Sarah Truong, Ahn R. Lee, Ladan Fazli, Varune R. Ramnarine, Jessica M. Lovnicki, Jackson Moore, Mike Wang, Jane Foo, Martin E. Gleave, Brett G. Hollier, Colleen Nelson, Colin Collins, Xuesen Dong, Ralph Buttyan
Journal: Clinical Cancer Research (2020)

Abstract Purpose: Patients with metastatic prostate cancer are increasingly presenting with treatment-resistant, androgen receptor–negative/low (AR−/Low) tumors, with or without neuroendocrine characteristics, in processes attributed to tumor cell plasticity. This plasticity has been modeled by Rb1/p53 knockdown/knockout and is accompanied by overexpression of the pluripotency factor, Sox2. Here, we explore the role of the developmental transcription factor Sox9 in the process of prostate cancer therapy response and tumor progression. Experimental Design: Unique prostate cancer cell models that capture AR−/Low stem cell–like intermediates were analyzed for features of plasticity and the functional role of Sox9. Human prostate cancer xenografts and tissue microarrays were evaluated for temporal alterations in Sox9 expression. The role of NF-κB pathway activity in Sox9 overexpression was explored. Results: Prostate cancer stem cell–like intermediates have reduced Rb1 and p53 protein expression and overexpress Sox2 as well as Sox9. Sox9 was required for spheroid growth, and overexpression increased invasiveness and neural features of prostate cancer cells. Sox9 was transiently upregulated in castration-induced progression of prostate cancer xenografts and was specifically overexpressed in neoadjuvant hormone therapy (NHT)–treated patient tumors. High Sox9 expression in NHT-treated patients predicts biochemical recurrence. Finally, we link Sox9 induction to NF-κB dimer activation in prostate cancer cells. Conclusions: Developmentally reprogrammed prostate cancer cell models recapitulate features of clinically advanced prostate tumors, including downregulated Rb1/p53 and overexpression of Sox2 with Sox9. Sox9 is a marker of a transitional state that identifies prostate cancer cells under the stress of therapeutic assault and facilitates progression to therapy resistance. Its expression may index the relative activity of the NF-κB pathway.
Consolidation Treatment with Y90-Ibritumomab Tiuxetan after R-Chop Induction in High-Risk Patients with Follicular Lymphoma (FL) (GOTEL-FL1LC): A Multicentric, Prospective Study
Authors: M. Provencio Pulla, M.A. Cruz Mora, J. Gomez Codina, C. Quero, M. Llanos, F.R. Garcia Arroyo, L. De La Cruz, J. Guma, J.R. Delgado, A. Rueda
Journal: Annals of Oncology (2012)
H3K27me3-mediated PGC1α gene silencing promotes melanoma invasion through WNT5A and YAP
Authors: Chi Luo, Eduardo Balsa, Elizabeth A. Perry, Jiaxin Liang, Clint D. Tavares, Francisca Vazquez, Hans R. Widlund, Pere Puigserver
Journal: Journal of Clinical Investigation (2020)

Oncogene-targeted and immune checkpoint therapies have revolutionized the clinical management of malignant melanoma and now offer hope to patients with advanced disease. Intimately connected to patients' overall clinical risk is whether the initial primary melanoma lesion will metastasize and cause advanced disease, but underlying mechanisms are not entirely understood. A subset of melanomas display heightened peroxisome proliferator-activated receptor γ coactivator 1-α (PGC1α) expression that maintains cell survival cues by promoting mitochondrial function, but also suppresses metastatic spread. Here, we show that PGC1α expression in melanoma cells was silenced by chromatin modifications that involve promoter H3K27 trimethylation. Pharmacological EZH2 inhibition diminished H3K27me3 histone markers, increased PGC1α expression, and functionally suppressed invasion within PGC1α-silenced melanoma cells. Mechanistically, PGC1α silencing activated transcription factor 12 (TCF12), to increase expression of WNT5A, which in turn stabilized YAP protein levels to promote melanoma migration and metastasis. Accordingly, inhibition of components of this transcription-signaling axis, including TCF12, WNT5A, or YAP, blocked melanoma migration in vitro and metastasis in vivo. These results indicate that epigenetic control of melanoma metastasis involved altered expression of PGC1α and an association with the inherent metabolic state of the tumor.
Quantitative Structure-Activity Relationships (QSARs) for Estrogen Binding to the Estrogen Receptor: Predictions across Species
Authors: Weida Tong, Roger Perkins, Richard Strelitz, Elizabeth R. Collantes, Susan Keenan, William J. Welsh, William S. Branham, Daniel M. Sheehan
Journal: Environmental Health Perspectives (1997)

The recognition of adverse effects due to environmental endocrine disruptors in humans and wildlife has focused attention on the need for predictive tools to select the most likely estrogenic chemicals from a very large number of chemicals for subsequent screening and/or testing for potential environmental toxicity. A three-dimensional quantitative structure-activity relationship (QSAR) model using comparative molecular field analysis (CoMFA) was constructed based on relative binding affinity (RBA) data from an estrogen receptor (ER) binding assay using calf uterine cytosol. The model demonstrated significant correlation of the calculated steric and electrostatic fields with RBA and yielded predictions that agreed well with experimental values over the entire range of RBA values. Analysis of the CoMFA three-dimensional contour plots revealed a consistent picture of the structural features that are largely responsible for the observed variations in RBA. Importantly, we established a correlation between the predicted RBA values for calf ER and their actual RBA values for human ER. These findings suggest a means to begin to construct a more comprehensive estrogen knowledge base by combining RBA assay data from multiple species in 3D-QSAR based predictive models, which could then be used to screen untested chemicals for their potential to bind to the ER. Another QSAR model was developed based on classical physicochemical descriptors generated using the CODESSA (Comprehensive Descriptors for Structural and Statistical Analysis) program. The predictive ability of the CoMFA model was superior to the corresponding CODESSA model.
A Multi-Center Phase II Study of Intra-Arterial Chemotherapy of a Fine-Powder Formulation of Cisplatin in Patients with Advanced Intrahepatic Cholangiocarcinoma
Authors: K. Nakachi, T. Okusaka, H. Iguchi, T. Shimamura, T. Ioka, A. Hosokawa, M. Ikeda, C. Morizane, A. Asagi, F. Junji
Journal: Annals of Oncology (2012)
リツキシマブと関連したB細胞リンパ腫上の抗CD19または抗CD38キメラ受容体との、T細胞養子免疫治療の相乗効果 | 文献情報 | J-GLOBAL 科学技術総合リンクセンター
Authors: Mihara K, Yanagihara K, Takigahira M, Takihara Y, Kimura A
Journal: Annals of Oncology (2008)
Prostate cancer: only one in four men with metastatic disease gets recommended chemotherapy
Authors: Jacqui Wise
Journal: BMJ (2020)

A national audit shows that only one in four men with advanced prostate cancer receives life prolonging chemotherapy despite its recommendation by the National Institute for Health and Care Excellence (NICE).

The National Prostate Cancer Audit’s annual report 2019 for England and Wales,1 published by the Royal College of Surgeons, reported for the first time on the use of primary docetaxel in metastatic disease. It found that only 27% of men with widespread disease received docetaxel, ranging from 0% to 39% by NHS providers in England.

Noel Clarke, consultant urological surgeon, and Heather Payne, consultant clinical oncologist, who were joint clinical leads for the audit, said that the …
Efficacy and Safety of Lumateperone for Treatment of Schizophrenia
Authors: Christoph U. Correll, Robert E. Davis, Michal Weingart, Jelena Saillard, Cedric O’Gorman, John M. Kane, Jeffrey A. Lieberman, Carol A. Tamminga, Sharon Mates, Kimberly E. Vanover
Journal: JAMA Psychiatry (2020)

<h3>Importance</h3> Individuals living with schizophrenia are affected by cardiometabolic, endocrine, and motor adverse effects of current antipsychotic medications. Lumateperone is a serotonin, dopamine, and glutamate modulator with the potential to treat schizophrenia with few adverse effects. <h3>Objective</h3> To examine the efficacy and safety of lumateperone for the short-term treatment of schizophrenia. <h3>Design, Setting, and Participants</h3> This randomized, double-blind, placebo-controlled, phase 3 clinical trial was conducted from November 13, 2014, to July 20, 2015, with data analyses performed from August 13 to September 15, 2015. Patients with schizophrenia who were aged 18 to 60 years and were experiencing an acute exacerbation of psychosis were enrolled from 12 clinical sites in the United States. <h3>Interventions</h3> Patients were randomized 1:1:1 (150 patients in each arm) to receive lumateperone tosylate, 60 mg; lumateperone tosylate, 40 mg (equivalent to 42 or 28 mg, respectively, of the active moiety lumateperone); or placebo once daily for 4 weeks. <h3>Main Outcomes and Measures</h3> The prespecified primary efficacy end point was mean change from baseline to day 28 in the Positive and Negative Syndrome Scale (PANSS) total score vs placebo. The key secondary efficacy measure was the Clinical Global Impression–Severity of Illness (CGI-S) score. The PANSS subscale scores, social function, safety, and tolerability were also assessed. <h3>Results</h3> The study comprised 450 patients (mean [SD] age, 42.4 [10.2] years; 346 [77.1%] male; mean [SD] baseline PANSS score, 89.8 [10.3]; mean [SD] baseline CGI-S score, 4.8 [0.6]). In the prespecified modified intent-to-treat efficacy analysis (n = 435), 42 mg of lumateperone met the primary and key secondary efficacy objectives, demonstrating a statistically significant improvement vs placebo from baseline to day 28 on the PANSS total score (least-squares mean difference [LSMD], −4.2; 95% CI, −7.8 to −0.6;<i>P</i> = .02; effect size [ES], −0.3) and the CGI-S (LSMD, −0.3; 95% CI, −0.5 to −0.1;<i>P</i> = .003; ES, −0.4). For 28 mg of lumateperone, the LSMD from baseline to day 28 was −2.6 (95% CI, −6.2 to 1.1;<i>P</i> = .16; ES, −0.2) on the PANSS total score and −0.2 (95% CI, −0.5 to 0.0;<i>P</i> = .02; ES, −0.3) on the CGI-S. Both lumateperone doses were well tolerated without clinically significant treatment-emergent motor adverse effects or changes in cardiometabolic or endocrine factors vs placebo. <h3>Conclusions and Relevance</h3> Lumateperone demonstrated efficacy for improving the symptoms of schizophrenia and had a favorable safety profile. <h3>Trial Registration</h3> ClinicalTrials.gov identifier:NCT02282761
Role of Temporary Ovarian Suppression Obtained with GNRH Analog in Reducing Premature Ovarian Failure (POF) Induced By Chemotherapy in Premenopausal Cancer Patients: a Meta-Analysis of Randomized Studies
Authors: L. Del Mastro, A. Levaggi, F. Poggio, S. Giraudi, C. Bighin, A. D'Alonzo, M. Lambertini, P. Pronzato, P. Bruzzi
Journal: Annals of Oncology (2012)
Diagnosis of coronary microvascular dysfunction in the clinic
Authors: Peter Ong, Basmah Safdar, Andreas Seitz, Astrid Hubert, John F Beltrame, Eva Prescott
Journal: Cardiovascular Research (2019)

Abstract The coronary microcirculation plays a pivotal role in the regulation of coronary blood flow and cardiac metabolism. It can adapt to acute and chronic pathologic conditions such as coronary thrombosis or long-standing hypertension. Due to the fact that the coronary microcirculation cannot be visualized in human beings in vivo, its assessment remains challenging. Thus, the clinical importance of the coronary microcirculation is still often underestimated or even neglected. Depending on the clinical condition of the respective patient, several non-invasive (e.g. transthoracic Doppler-echocardiography assessing coronary flow velocity reserve, cardiac magnetic resonance imaging, positron emission tomography) and invasive methods (e.g. assessment of coronary flow reserve (CFR) and microvascular resistance (MVR) using adenosine, microvascular coronary spasm with acetylcholine) have been established for the assessment of coronary microvascular function. Individual patient characteristics, but certainly also local availability, methodical expertise and costs will influence which methods are being used for the diagnostic work-up (non-invasive and/or invasive assessment) in a patient with recurrent symptoms and suspected coronary microvascular dysfunction. Recently, the combined invasive assessment of coronary vasoconstrictor as well as vasodilator abnormalities has been titled interventional diagnostic procedure (IDP). It involves intracoronary acetylcholine testing for the detection of coronary spasm as well as CFR and MVR assessment in response to adenosine using a dedicated wire. Currently, the IDP represents the most comprehensive coronary vasomotor assessment. Studies using the IDP to better characterize the endotypes observed will hopefully facilitate development of tailored and effective treatments.
Prognostic Value of KI-67 Labeling Index in Patients with Ductal Intraepithelial Neoplasia of the Breast. Postsurgical Outcome for 1171 Women Cared for in One Single Institution Over 10 Years
Authors: M. Lazzeroni, E. Botteri, A. Guerrieri Gonzaga, M.C. Leonardi, D. Serrano, A. De Censi, N. Rotmensz, C. Varricchio, B. Bonanni, G. Puneri
Journal: Annals of Oncology (2012)
O-0013 Improved Early Prediction of Individual Prognosis for Patients with Metastatic Colorectal Cancer: Joint Modeling of Tumor Shrinkage with Volume Data
Authors: Volker Heinemann, Ruediger Laubender, Ute Sartorius, Clemens Giessen, Anno Graser, Ulrich Mansmann
Journal: Annals of Oncology (2012)
Cerebel (EGF111438): An Open Label Randomized Phase III Study Comparing the Incidence of CNS Metastases in Patients (PTS) with HER2+ Metastatic Breast Cancer (MBC), Treated with Lapatinib Plus Capecitabine (LC) Versus Trastuzumab Plus Capecitabine (TC)
Authors: X. Pivot, V. Semiglazov, B. Żurawski, R. Allerton, A. Fabi, E. Ciruelos, R. Parikh, M. DeSilvio, S. Santillana, R. Swaby
Journal: Annals of Oncology (2012)
The Predictive and Prognostic Role of O6-Methylguanine-DNA Methyltransferase (MGMT) and Tissue Transglutaminase-2 (TGASE-2) in Metastatic Renal Cell Carcinoma (MRCC) Patients Treated with Sunitinib
Authors: D. Tunali, B. Sarsık, R. Durusoy, S. S¸en, E. Gökmen
Journal: Annals of Oncology (2012)
Workforce crisis has left mental health staff at “breaking point” as demand rises
Authors: Elisabeth Mahase
Journal: BMJ (2020)

Staff working in mental healthcare are at “breaking point” as they try to handle rising demand with a continuous staffing gap, a survey by the BMA has found.1

Of more than 1000 mental health professionals surveyed, 63% said that they worked in a setting that had rota gaps across the team, and 69% of these said that such gaps occurred either most or all the time.

As a result, over half (52%) of the respondents reported being too busy to provide the care they would like to, while 44% said their workload was unmanageable. Sharing their personal experiences, one respondent said that they had been “thrown to the wolves,” while another said that the stress had negatively affected their own mental health. …
The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial
Authors: Hertzel C Gerstein, Robert Hart, Helen M Colhoun, Rafael Diaz, Mark Lakshmanan, Fady T Botros, Jeffrey Probstfield, Matthew C Riddle, Lars Rydén, Charles Messan Atisso, Leanne Dyal, Stephanie Hall, Alvaro Avezum, Jan Basile, Ignacio Conget, William C Cushman, Nicolae Hancu, Markolf Hanefeld, Petr Jansky, Matyas Keltai, Fernando Lanas, Lawrence A Leiter, Patricio Lopez-Jaramillo, Ernesto Germán Cardona Muñoz, Nana Pogosova, Peter J Raubenheimer, Jonathan E Shaw, Wayne H-H Sheu, Theodora Temelkova-Kurktschiev
Journal: The Lancet Diabetes & Endocrinology (2020)
An Exploratory Analysis of AMPK and ACC Activation in Colorectal Primary Tumors and their Corresponding Metastasis
Authors: F. Bergamo, G. Griguolo, E. Zulato, G. Esposito, M. Nardin, C. Mescoli, M. Rugge, V. Zagonel, S. Lonardi, S. Indraccolo
Journal: Annals of Oncology (2012)
Bevacizumab Plus Metronomic Cyclophosphamide for Heavily Pretreated Ovarian Cancer: A Single Institution Experience
Authors: I. Ghanem, C. Mendiola, A. Diaz, G. Velasco, L. Manso, E. Ciruelos, R.A. Manneh, S. Hoyos, T. Pascual, H. Cortes-Funes
Journal: Annals of Oncology (2012)
A human ciliopathy reveals essential functions for NEK10 in airway mucociliary clearance
Authors: Raghu R. Chivukula, Daniel T. Montoro, Hui Min Leung, Jason Yang, Hanan E. Shamseldin, Martin S. Taylor, Gerard W. Dougherty, Maimoona A. Zariwala, Johnny Carson, M. Leigh Anne Daniels, Patrick R. Sears, Katharine E. Black, Lida P. Hariri, Ibrahim Almogarri, Evgeni M. Frenkel, Vladimir Vinarsky, Heymut Omran, Michael R. Knowles, Guillermo J. Tearney, Fowzan S. Alkuraya, David M. Sabatini
Journal: Nature Medicine (2020)
Homogeneity of EGFR Mutation in Patients with Resected Adenocarcinoma of the Lung
Authors: L.K. Chi, L.Y. Kwan, T.K. Fai, J. Tong, C. Wu, M. Hsin, E. Chung, C. Wong, T.M.S. Kam
Journal: Annals of Oncology (2012)
PD-0003 Comparison of GD-EOB-DTPA Enhanced Mri and Contrast-Enhanced Intraoperative Ultrasound using Sonazoid in Patients Undergoing Liver Resection for Colorectal Liver Metastasis
Authors: Junichi Arita, Nobuyuki Takemura, Ryuji Yoshioka, Ono Yoshihiro, Fumitake Suzuki, Rintaro Koga, Takeshi Sano, Akio Saiura, Toshiharu Yamaguchi
Journal: Annals of Oncology (2012)
Symptomatic Changes to Predict Disease Control by Chemotherapy for Pancreatic Cancer
Authors: A. Kuwahara, S. Mitsunaga, M. Ikeda, I. Ohno, S. Shimizu, H. Takahashi, H. Okuyama, T. Okusaka, H. Ueno, C. Morizane, S. Kondo
Journal: Annals of Oncology (2012)
Emerging roles of IL-34 in health and disease
Authors: Iva Lelios, Dilay Cansever, Sebastian G. Utz, Wiebke Mildenberger, Sebastian A. Stifter, Melanie Greter
Journal: The Journal of Experimental Medicine (2020)

Macrophages are part of the innate immune system and are present in every organ of the body. They fulfill critical roles in tissue homeostasis and development and are involved in various pathologies. An essential factor for the development, homeostasis, and function of mononuclear phagocytes is the colony stimulating factor-1 receptor (CSF-1R), which has two known ligands: CSF-1 and interleukin-34 (IL-34). While CSF-1 has been extensively studied, the biology and functions of IL-34 are only now beginning to be uncovered. In this review, we discuss recent advances of IL-34 biology in health and disease with a specific focus on mononuclear phagocytes.
GDF15 Induces Anorexia through Nausea and Emesis
Authors: Tito Borner, Evan D. Shaulson, Misgana Y. Ghidewon, Amanda B. Barnett, Charles C. Horn, Robert P. Doyle, Harvey J. Grill, Matthew R. Hayes, Bart C. De Jonghe
Journal: Cell Metabolism (2020)
Recursive Partitioning for New Classification of Patients with Esophageal Cancer Treated by Chemoradiotherapy
Authors: M. Nomura, K. Shitara, T. Kodaira, C. Kondoh, D. Takahari, T. Ura, H. Kojima, M. Kamata, K. Muro, S. Sawada
Journal: Annals of Oncology (2012)
Molecular Profiling as an Outcome Predictor in the Galaxy Trialtm (NCT01348126): A Randomized IIB/III Study of Ganetespib (STA-9090) in Combination with Docetaxel Versus Docetaxel Alone in Subjects with Stage IIIB/IV NSCLC
Authors: R. Rosell, S.S. Ramalingam, D. Fennell, C. Manegold, I. El Hariry, V. Vukovic, F. Teofilovici, V. Reichert, G. Goss
Journal: Annals of Oncology (2012)
P-0191 Body Mass Index Category or Dietary Habits are Better Associated To Colorectal Cancer? Data From A Greek Case Control Study
Authors: Niki Kontou, Theodora Psaltopoulou, Nick Soupos, Evangelos Polychronopoulos, Dimitrios Xinopoulos, Athena Linos, Meletios Dimopoulos, Demosthenes Panagiotakos
Journal: Annals of Oncology (2012)
한국인 Gilbert 증후군 환자에서 UGT-1Al 유전자 다형성에 관한 연구
Authors: 김윤홍(Yoon Hong Kim), 연종은(Jong Eun Yeon), 정길만(Gil Man Jung), 김효정(Hyo Jung Kim), 김재선(Jae Seon Kim), 변관수(Kwan Soo Byun), 박영태(Young Tae Bak), 이창홍(Chang Hong Lee)
Journal: Clinical and Molecular Hepatology (2002)

목적 : Gilbert 증후군은 UDP-glucuronosyltransferas(UGT-1A1)의 활성도가 정상인의 30%정도로 감소하여 발생한다고 알려져 왔다. 알려진 바에 의하면 UGT-1A1의 promoter A(TA)TAA 부위에 변이가 발생하여 부가적인 수의 염기가 존재해서 (TA)7/7 이나 (TA)6/7을 이루게 되면 Gilbert 증후군이 발생하게 되며 이러한 변이의 발생 빈도나 양상은 인종에 따라 차이를 보인다고 알려져 있다. 저자는 한국인 Gilbert 증후군 환자에서의 UGT-1A1의 promoter 변이의 빈도 및 발현 양상을 확인하고자 하였다. 대상과 방법 : Gilbert 증후군 환자 12명과 정상 대조군 20명을 대상으로 하였으며 각각의 대상군의 혈액에서 DNA를 분리한 후 direct sequencing을 시행한 후 양군에서의 UGT-1A1의 promoter 부위 A(TA)TAA 변이를 비교 분석하였다. 결과 : 1) Gilbert 증후군 환자 총 12예 중에서 5예는 A(TA)6/6TAA homozygote를 보였고 5예는 (TA)6/7TAA heterozygote를 보였다. 나머지 2예에서는 A(TA)7/7TAA homozygote를 보여서 총 A(TA)TAA 유전자 변이율은 58.3%를 보였다. 2) 건강 대조군 20예 중 17예는 A(TA)6/6TAA homozygote를 보였으며 2예는 A(TA)6/7TAA heterozygote를 보였다. 나머지 1예는 A(TA)7/7TAA homozygote를 보여서 A(TA)TAA 유전자 변이율은 15%를 보였다. 3) Gilbert 증후군 환자에서의 A(TA)TAA 유전자 변이율은 건강 대조군에서의 변이율에 비하여 통계적으로 유의하게 더 높았다 (p=0.018). 결론 : 한국인 Gilbert 증후군 환자에서의 UGT-1A1의 promoter A(TA)TAA 유전자 변이율은 대조군에 비하여 유의하게 더 높았으나 이러한 변이가 없는 Gilbert 증후군 환자도 다수 있어서 이 변이가 한국인에서 Gilbert 증후군을 일으키는 유일한 원인은 아닐 것으로 생각된다. 향후 다른 UGT-1A1 염색체의 변이와 Gilbert 증후군과의 관계를 규명하는 연구들이 필요하리라 생각된다.
Abstract 9971: Low Levels of Hemoglobin A1c Are Associated With Higher Cardiovascular Mortality in a General Population Without Medication for Diabetes
Authors: Hisako Tsuji, Hiroyuki Sueyoshi, Yuzo Akita, Ichiro Shiojima
Journal: Circulation (2019)

Background: Although there is increasing recognition of the risks associated with hypoglycemia in patients with diabetes, only a few studies have examined the association in the general population ...
Long-term colorectal cancer incidence after adenoma removal and the effects of surveillance on incidence: a multicentre, retrospective, cohort study
Authors: Amanda J Cross, Emma C Robbins, Kevin Pack, Iain Stenson, Paula L Kirby, Bhavita Patel, Matthew D Rutter, Andrew M Veitch, Brian P Saunders, Stephen W Duffy, Kate Wooldrage
Journal: Gut (2020)

Postpolypectomy colonoscopy surveillance aims to prevent colorectal cancer (CRC). The 2002 UK surveillance guidelines define low-risk, intermediate-risk and high-risk groups, recommending different strategies for each. Evidence supporting the guidelines is limited. We examined CRC incidence and effects of surveillance on incidence among each risk group.